FDA OKs label update for etravirine

Article

FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral agents.

FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral (ARV) agents.

The recommended oral dose of etravirine tablets is 200 mg (one 200-mg tablet or two 100-mg tablets) taken twice a day following a meal. The new 200-mg product formulation is expected to launch in the United States sometime this month. The 100-mg tablet will remain available.

Patients who are unable to swallow etravirine tablets whole may disperse the tablets in a glass of water.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.